Question to the Department of Health and Social Care:

To ask His Majesty's Government what treatments exist for those mantle cell lymphoma patients unable to access allogeneic stem cell transplants due to (1) ethnicity, (2) age, and (3) ethnicity and age.

A number of National Health Service treatment options are available for patients with mantle cell lymphoma, and may include:

- chemotherapy plus rituximab;

- autologous stem cell transplant;

- ibrutinib;

- zanubrutinib;

- brexucabtagene autoleucel, a type of chimeric antigen receptor T-cell therapy; and/or

- supportive care.

None of these treatments are precluded on the basis of ethnicity, age, or a combination of the two, but available options will be dependent on individual clinical circumstances and any prior treatment or treatments received.

Potential treatment options are also currently being appraised by the National Institute for Health and Care Excellence and therefore could be made available within England in the future, subject to positive recommendations on NHS adoption being reached. These are: Acalabrutinib with bendamustine and rituximab; and Ibrutinib with R-CHOP.